BMS and PsiOxus Therapeutics Expand their 2016 Immuno-Oncology Collaboration

 BMS and PsiOxus Therapeutics Expand their 2016 Immuno-Oncology Collaboration

BMS and PsiOxus Therapeutics Expand their 2016 Immuno-Oncology Collaboration

Shots:

  • In the P-I SPICE study, the companies will evaluate the clinical combination of BMS’ Opdivo with PsiOxus’ NG-641 and optimize the combination IV dosing regimen in late-stage cancer patients to treat a range of tumor types
  • PsiOxus will be responsible to conduct P-I study with patient recruitment expected to initiate in Q3’21
  • NG-641 is a tumor re-engineering product using PsiOxus’ T-SIGn platform based upon the enadenotucirev vector while Opdivo is a PD-1 immune checkpoint inhibitor, designed to harness the body’s own immune system to help restore anti-tumor immune response

Click here to­ read full press release/ article | Ref: Businesswire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post